Inhalable insulin - Wikipedia, the free encyclopedia
Exubera is considered a short or rapid acting insulin. In clinical studies, Exubera reached peak concentration levels faster than some insulins administered by injection. [2]
MannKind Corporation - Wikipedia, the free encyclopedia
Unfortunately, the investment community and the pharmaceutical industry, haunted by the failures of Pfizer's Exubera, remain unconvinced that there is any meaningful market for ...
Exubera
Exubera is a medication used to control blood sugar in people with type 1 or type 2 diabetes. This eMedTV article offers an overview on the medication, including how it works ...
Diabetes - Exubera: what went wrong?
In a statement at their website, Pfizer has announced they are discontinuing the sale of their inhaled insulin product, Exubera: "we made an important ...
BioWorld Today
Washington Editor. Nektar Therapeutics Inc. said it will cease all spending and partnership talks for Exubera after a new analysis of clinical trial data revealed an increased risk ...
RxAmerica
ISSUE: Pfizer announces market discontinuation of Exubera (insulin human inhalation powder) for financial reasons: MEDICATION: Exubera® (insulin human inhalation powder)
Exubera, Safety, and No Guarantees. In the Pipeline:
About this Author Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt ...
And You Thought Exubera Was A Disaster Before. In the Pipeline:
About this Author Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt ...
Exubera becoming a big disappointment for Pfizer - FierceBiotech
With patients put off by Exubera's difficult dosing device, insurers reluctant to foot the bill and doctors concerned about its long-term impact on patients' health, sales of ...
Diabetes Monitor - inhaled insulin
Exubera is currently also under review by the European Medicines Evaluation Agency … Exubera is being developed for patients with type 1 and type 2 diabetes through a ...
